Predictors of Cognitive Outcomes in Geriatric Depression (NBOLD)

Phenotype Predictors of Cognitive Outcomes in Geriatric Depression

This study will focus on examining effects of stress on long-term mood and cognitive outcomes of late-life depression. It will also example the neural underpinnings of these changes using structural and functional brain imaging. Understanding how effects of stress in older depressed adults, as well as factors that might minimize those effects, lead to particular mood and cognitive outcomes will inform future development of novel prevention strategies.

Study Overview

• Status: Active, not recruiting
• Conditions: Stress; Cognitive Change; Major Depressive Disorder; Neuroticism
• Intervention / Treatment: Drug: Sertraline, bupropion, desvenlafaxine

Detailed Description

In this renewal of R01MH108578, the investigators are seeking to extend findings from the initial study to focus on effects of stress in longitudinal mood and cognitive outcomes of late-life depression (LLD) and to examine stress effects on brain structure and function in LLD. Severe or persistent stressors can result in a number of behavioral and mood changes, including anxiety, dysphoric mood, sleep disruption, altered appetite, and withdrawal from social and pleasurable activities. These stress-related consequences are particularly salient when considering longitudinal outcomes of treated LLD. They may be compounded by an individual's longstanding maladaptive patterns of response to stress, embodied in the construct of neuroticism, which the investigators have shown to be related to poor mood and cognitive LLD outcomes. Moreover, Andreescu et al. (2019) introduced a model of depression recurrence that incorporates the homeostatic disequilibrium hypothesis, which proposes that in geriatric remitted depression, neural networks are in fragile homeostasis that is threatened by stress exposure. Networks of particular importance in stress of LLD outcome are the Default Mode Network (DMN), Salience Network (SN) and Executive Control Network (ECN).

The Neurobiology of Late Life Depression (NBOLD) study began enrolling older depressed and never depressed controls in 2013, enrolling 132 depressed and 44 controls, and currently follows 77 depressed and 22 controls. Subjects are well characterized in terms of mood, cognition, personality and stress (including specific measures obtained during the present COVID pandemic). It is well suited to examine stress effects on longitudinal mood and cognitive outcomes. For the renewal, the study will follow current subjects and recruit 75 new subjects, who will be followed for up to 5 years with annual cognitive testing, stress measures and baseline and two-year functional brain magnetic resonance imaging (fMRI) scan.

In this renewal, the investigators will examine the following specific aims:

1. To study effects of stressors (obtained on a variety of measures) and neuroticism on longitudinal mood and cognitive outcomes in older adults with history of major depressive disorder (MDD).
2. To study effects of stress and neuroticism on brain structure and function in older adults with MDD history.
3. To explore relationships among variables in Aims 1 and 2 with longitudinal multivariable statistical models.

• Study Type: Interventional
• Enrollment (Estimated): 75
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Connecticut
    • Farmington, Connecticut, United States, 06030
      • UConn Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• major depression, single episode or recurrent;
• ability to read and write English;
• Mini-Mental State Examination >25.

Exclusion Criteria:

• lifetime alcohol/drug dependence
• conditions associated with brain abnormalities such hydrocephalus, benign and cancerous brain tumors, epilepsy, Parkinson's disease, Huntington's chorea, dementia, demyelinating diseases, etc.
• untreated endocrine disorder other than diabetes mellitus
• established clinical diagnosis of dementia
• other primary psychiatric disorders, e.g., panic disorder, social phobia, obsessive- compulsive disorder, schizoaffective disorder, schizophrenia, bipolar disorder

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: Depressed; Subjects receive FDA-approved antidepressants

Drug: Sertraline, bupropion, desvenlafaxine; Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.; Other Names: Wellbutrin; Zoloft; Pristiq

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Montgomery-Asberg Depression Rating Scale (MADRAS)	Measure of depression severity and Recurrence of Depression Minimum Score = 0; Maximum Score = 60; Higher score means worse outcome	Three years
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery Total Score	Global cognitive measure; Minimum Score = 0; Maximum Score = 100; Higher score means better outcome	Three years
Cognitive clinical diagnosis	Participant records will be reviewed annually by the consensus panel. The study will convene a panel of experts to review each case, including the PI, treating geriatric psychiatrists and study neuropsychologist. Panel members review the following information for each participant: 1) initial evaluation and most recent clinical depression study notes, 2) neuropsychological testing profiles, 3) informant report of cognitive decline based on the Dementia Severity Rating Scale, 4) study structural MRI images to determine vascular burden, and 5) additional neurological and clinical neuropsychological consultations when available. The panel discusses the case until a consensus cognitive diagnosis is reached.	three years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Functional brain magnetic resonance imaging (fMRI) scan changes in resting state functional connectivity.	A change in the strength of connectivity within a network and between two networks will be determined by comparing the strength of connectivity at baseline and at two years. The functional connectivity strength is reflected by a z score of normalized Pearson correlation coefficient using the Fisher transformation.	Two years
Functional brain magnetic resonance imaging (fMRI) scan structural imaging changes	Measures from structural imaging in the key brain regions will be the volumetric measurement from T1-weighted MRI. A change in the volume of a brain structure will be determined by subtracting the regional volume at baseline from two years.	Two years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neuroticism subtest score on NEO Personality Inventory	Neuroticism domain and its subdomains will be examined; Minimum Score = 0; Maximum Score = 92; Higher score means worse outcome	Three years

Collaborators and Investigators

• Sponsor: David Steffens
• Collaborators: National Institute of Mental Health (NIMH)
• Investigators: Principal Investigator: David Steffens, M.D., M.H.S., UConn Health

Study record dates

Study Major Dates

• Study Start (Actual): September 28, 2021
• Primary Completion (Estimated): April 30, 2027
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: December 13, 2021
• First Submitted That Met QC Criteria: March 1, 2022
• First Posted (Actual): March 10, 2022

Study Record Updates

• Last Update Posted (Actual): May 22, 2026
• Last Update Submitted That Met QC Criteria: May 19, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Late Life Depression
• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Depressive Disorder; Depressive Disorder, Major; Organic Chemicals; Lipids; Hydrocarbons; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Amines; Phenols; Benzene Derivatives; Alcohols; Ketones; Cyclohexanols; Hexanols; Fatty Alcohols; Propiophenones; 1-Naphthylamine; Desvenlafaxine Succinate; Bupropion; Sertraline
• Other Study ID Numbers: IE-13-048H-6.1; R01MH108578 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: This R01 will develop important new data on 75 subjects. These data will be available to investigators both within UConn and outside the institution.
• IPD Sharing Time Frame: Starting 6 months after publication

IPD Sharing Access Criteria

Potential investigators will gain knowledge of the project through NIH Reporter and through Dr. Steffens' UConn webpage. They will be able to contact Dr. Steffens and he will work with the investigator to determine the nature of what the investigator wishes to study to ensure that he/she has a complete data set that will allow for a successful analysis. Dr. Steffens' team will create an anonymized data set, encrypt it, and electronically transfer it to the investigator.

Dr. Steffens will maintain a list of approved analyses and track progress of manuscripts and publications. In addition, consistent with National Institute of Mental Health (NIMH)requirements, Dr. Steffens will plan to submit data via the NIMH Data Archive (NDA).

• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No